title: Fc gamma receptor-mediated biological activities of human leukemic cell lines and their modulation by transforming growth factor-beta 1 and interleukin 6.
abstract: Previously we reported that transforming growth factor-beta 1 (TGF-beta 1) remarkably enhanced the differentiation of human leukemic cell lines, HL-60 and THP-1, in the presence of 1 alpha,25-dihydroxyvitamin D3 (VD3) and also that it induced Fc receptor for immunoglobulin G (Fc gamma R), type IIIB, in the presence of retinoic acid (RA). The present study revealed that TGF-beta 1 enhanced the Fc gamma RI- and Fc gamma RII-mediated antibody-dependent cellular cytotoxicity (ADCC) of the cells differentiated in the presence of VD3 and RA. However, production of active oxygen molecules was suppressed by TGF-beta 1. On the other hand, IL-6 stimulated production of active oxygen molecules and ADCC of the cells treated with VD3 and tumor necrosis factor-alpha (TNF-alpha). Furthermore, the levels of cell surface Fc gamma RI and Fc gamma RII were not clearly correlated with the ADCC. The TGF-beta 1/VD3-treated HL-60 cells were able to synthesize mRNAs for TGF-beta 1 and TNF-alpha, although TNF-alpha protein was not detectable. These results suggest that TGF-beta 1 has a bifunctional role, either stimulatory or inhibitory, in the modulation of macrophage activities through Fc gamma Rs and that IL-6 stimulates certain macrophage activities in mature cells.
authors.affiliation: Tokyo Institute for Immunopharmacology, Inc., Chugai Pharmaceutical Co., Ltd., Japan.
authors.forename: M
authors.initials: M
authors.lastname: Morikawa
authors.forename: N
authors.initials: N
authors.lastname: Harada
authors.forename: Y
authors.initials: Y
authors.lastname: Nunomura
authors.forename: T
authors.initials: T
authors.lastname: Koike
authors.forename: S
authors.initials: S
authors.lastname: Hashimoto
authors.forename: G
authors.initials: G
authors.lastname: Soma
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
mesh_terms: D000920:Antibody-Dependent Cell Cytotoxicity; D015152:Blotting, Northern; D002117:Calcitriol / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D002462:Cell Membrane / Q000276:immunology / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000494:pharmacology*; D007948:Leukemia, Monocytic, Acute; D015473:Leukemia, Promyelocytic, Acute; D008163:Luminescent Measurements; D012333:RNA, Messenger / Q000096:biosynthesis / Q000302:isolation & purification; D017452:Receptors, IgG / Q000096:biosynthesis / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins / Q000494:pharmacology; D013481:Superoxides / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000096:biosynthesis* / Q000494:pharmacology*; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
chemical_list: D015850:Interleukin-6; D012333:RNA, Messenger; D017452:Receptors, IgG; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D013481:Superoxides; D014212:Tretinoin; D002117:Calcitriol